This result may explain the low frequency of EGFR amplification in HNSCC from other studies, generally reported as 10% to 30%.37,38 Patients showing EFGR amplification might represent a better candidate for EGFR-targeted chemotherapy. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.